stars 1 stars 2 stars 3

BetaBlue is an early stage biopharmaceutical company seeking to commercialize functionally selective ligands for the D2 dopamine receptor with the goal of improved efficacy in treating the negative and cognitive symptoms of schizophrenia. We are also pursuing development for dyskinesia & dystonia, substance use disorders, and Huntington's disease.

BetaBlue Questions

The BetaBlue annual revenue was $4 million in 2026.

BetaBlue is based in Dover, Delaware.

The NAICS codes for BetaBlue are [325, 32541, 3254, 32].

The SIC codes for BetaBlue are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users